Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 39.6% in the third quarter, HoldingsChannel reports. The firm owned 39,761 shares of the biopharmaceutical company’s stock after selling 26,114 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Regeneron Pharmaceuticals were worth $30,150,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter worth $26,000. Armstrong Advisory Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 28 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $29,000. Trust Co. of Vermont acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $29,000. Finally, Fiduciary Financial Advisors purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Marion Mccourt sold 1,131 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the transaction, the executive vice president directly owned 12,003 shares in the company, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Murphy sold 4,147 shares of the stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock worth $6,506,845 in the last three months. Company insiders own 6.97% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: TD Cowen raised its price target to $980 from $960 while maintaining a positive view of Regeneron, signaling potential upside from current levels. TD Cowen raises target for Regeneron stock
• Positive Sentiment: Analysts and investors continue to point to Regeneron’s growth potential, including strong Dupixent performance and positive Phase 3 OPTIMA results for investigational pasatru in fibrodysplasia ossificans progressiva. The company is also working to build a broader global oncology business. Regeneron growth potential analysis
• Neutral Sentiment: Regeneron is scheduled to report quarterly results next week. Analysts expect earnings to grow, but the company reportedly lacks the typical combination of estimate revisions and other indicators associated with a likely earnings beat, creating uncertainty ahead of the release. Regeneron earnings expectations
• Neutral Sentiment: Recent coverage describes REGN as a relatively steady stock and notes that it gained in the prior session, although it lagged some competitors. This provides limited new information about the company’s fundamentals. Regeneron stock performance versus competitors
• Negative Sentiment: Valuation-related commentary asks whether Regeneron is priced too highly relative to pharmaceutical peers, which could limit near-term upside and encourage profit-taking ahead of earnings. Regeneron valuation versus rivals

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $805.02 on Monday. The stock has a market capitalization of $82.88 billion, a P/E ratio of 19.90, a PEG ratio of 1.36 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a one year low of $575.93 and a one year high of $859.34. The company has a 50 day moving average price of $791.86 and a two-hundred day moving average price of $722.88.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the firm posted $12.81 EPS. Regeneron Pharmaceuticals’s revenue was up 16.7% on a year-over-year basis. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Wall Street Analyst Weigh In

A number of research firms recently commented on REGN. The Goldman Sachs Group increased their price objective on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a research note on Friday, July 31st. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. UBS Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $660.00 to $978.00 in a research note on Thursday, October 15th. Piper Sandler upped their target price on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the company an “overweight” rating in a report on Monday, October 19th. Finally, Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $846.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.